Mon panier

ADC Isotype Control Mouse IgG2a (MMAE)

Avis des utilisateurs
Numéro de produit/spécification
Prix
Qté
DNP-BM487-100ug
$195.00
DNP-BM487-1mg
$790.00
ETA of in-stock products:2 business days
Total des articles Montant du produit$ 0

Détails du produit

  • Source

    ADC Isotype Control Mouse IgG2a (MMAE) is a recombinant mouse monoclonal antibody expressed in HEK293 cells.

  • Antibody Type

    Recombinant Monoclonal

  • Isotype

    Mouse IgG2a, Kappa

  • Host Species

    Mouse

  • Purification

    Protein A purified / Protein G purified.

  • Aggregation

    Less than 5%, as determined by SEC-MALS.

  • Concentration

    Please refer to the Certificate of Analysis (CoA).

  • Form

    Lyophilized

  • Formulation

    Lyophilized from a 0.22 μm-filtered solution in PBS (pH 7.4), with trehalose as protectant.

    Please contact us for customized product forms or formulations.

  • Reconstitution

    Please refer to the Certificate of Analysis (CoA) for specific instructions.

  • Shipping

    Lyophilized product is shipped at ambient temperature.

  • Storage

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
  • Notices

    Product Specific Notices: For research use only.

  • ACRO Quality Management System

    1. QMS(ISO, GMP)
    2. Quality Advantages
    3. Quality Control Process

Les clients ont également consulté

Avis des utilisateurs
Publier un commentaire

Introduction de fond

MMAE (Monomethyl auristatin E) is a synthetic microtubule inhibitor. It binds to tubulin to prevent microtubule polymerization, inducing tumor cell cycle arrest and apoptosis. As a highly toxic payload commonly used in ADCs, it has excellent plasma stability; when conjugated to antibodies, it can precisely kill target cells and is widely applied in the R&D of ADC drugs for hematological malignancies and solid tumors.

Progrès de frontière

 
Drug Candidate Licensing
More
  • Informations de base sur le produit
  • Détails du produit
  • Les clients ont également consulté
  • Avis des utilisateurs
  • Contexte